OR WAIT null SECS
The Asia-Pacific (APAC) asthma therapeutics market-covering India, China, Australia, South Korea, and Japan-is predicted to rise 5.4%, from $4.1 billion in 2016 to around $6 billion by 2023, according to business intelligence provider GBI Research.
The company’s latest report states that this strong growth will be driven by an expanding aging population, increases in air pollution, a promising product pipeline, and the launch of first-in-class molecules.
An increase in biologic development in the asthma market is possibly attributable to the success of Xolair (omalizumab), one of the currently marketed mAbs, which reached blockbuster status in 2014. The drug was approved in 2003 in India, Australia, Japan, and South Korea, as an add-on therapy for those aged 12 and over with moderate-to-severe allergic asthmas and symptoms not adequately controlled with inhaled corticosteroids. It was the first biologic to reach the APAC asthma market, and its launch addressed a significant unmet need for personalized therapy in asthma.
View the full report here.